<DOC>
	<DOCNO>NCT00320424</DOCNO>
	<brief_summary>This study request PMDA confirm efficacy safety HFS .</brief_summary>
	<brief_title>Hip Fracture Study GSK576428 ( Fondaparinux Sodium )</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients undergo hip fracture surgery within 10 day follow time fracture hip ( proximal femur ) ( follow time fracture estimate trauma ) . Active , clinically significant bleeding ( exclude drainage ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>MOSLL</keyword>
	<keyword>VTE</keyword>
	<keyword>Xa factor</keyword>
	<keyword>pentasaccharide</keyword>
</DOC>